Skip to main content
OpenTrials
Completed

NCT Number: NCT04312971

Norepinephrine Infusion During Cardiopulmonary Bypass

The primary objective is to test the efficacy and safety of the accuracy of continuous intravenous infusion of norepinephrine during cardiopulmonary bypass (CPB) on the prevention of hyperlactatemia after cardiac surgery.

"Efficacy" would be tested with measurement of the postoperative changes in lactic acid level over time from the baseline value before induction of general anesthesia.

"safety" would be tested with observing the post-cardiotomy need for inotropic and vasopressor support, the incidence of postoperative acute kidney injury (AKI), changes in cardiac troponin level (CnTnI), and signs of ischemic splanchnic injury.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dammam University, Khobar, Eastern Province, Saudi Arabia

Loading trial locations.

About this study

Rationale

1.1. Vasoplegia and cardiac surgery:

Vasoplegia Syndrome (VS), prevailing in about 20% of cardiac surgical procedures (1), is defined as low mean arterial pressure (MAP) with normal or high cardiac indices and which is resistant to treatment with the commonly used vasopressors. (2,3) Vasoplegia might occur either during or after the cardiopulmonary bypass periods or during the postoperative period during the intensive care unit (ICU) stay. (3) Many factors have been found to be related to the increased Vasoplegia during the cardiopulmonary bypass period such as left ventricular ejection fraction more than 40%, male patients, elderly patients, higher body mass index, long cardiopulmonary bypass time, hypotension upon the start of cardiopulmonary bypass, perioperative use of angiotensin-converting enzyme inhibitors (ACE) and presence of infective endocarditis. (4,5)

1.2. Effects of Cardiopulmonary bypass (CPB) on Post cardiotomy Vasoplegia.

Cardiopulmonary bypass itself may intensify the effects of vasoplegia due to hemodilution which decreases the blood viscosity, so, reducing the overall peripheral vascular resistance. Moreover, the interaction of blood with the tubing of the cardiopulmonary bypass machine results in the release of inflammatory mediators which play an important role in reducing the peripheral resistance and aggravating the hypotension. Although compensatory and auto-regulatory mechanisms play an important role in maintaining adequate tissue perfusion, hypotension during the cardiopulmonary bypass period may result in poor outcomes as postoperative stroke (4) especially if the mean arterial pressure is below 65 mmHg. (6)

1.3. Hyperlactatemia after cardiac surgery

Lactate was used as a marker for adequate tissue perfusion since the mid-1800s. Although the literature has illustrated the undesirable effects of high lactate levels, however, the cause, the prevention as well as treatment measures of hyperlactatemia remain obscure. Additionally, lactic acidosis or hyperlactatemia might occur in cases of refractory vasoplegia. A rise in lactate levels is common during cardiac surgery and is well known for its deleterious and its association with poor patients' outcomes. (7)

Owing to its detrimental effects, measures to reduce the effects and treat vasoplegia were used. Firstly, excluding any equipment or mechanical failure such as the arterial line monitor, adjusting the bypass flows for higher cardiac index (CI>2.2), confirming the proper cannula position and ruling out any aortic dissection.

Secondly, adjusting some physiological parameters is of great value as checking hematocrit level for excessive hemodilution, adjusting the anesthetics with severe vasodilatory properties, excluding the possibility of a drug reaction or anaphylaxis and temperature management during hypothermic bypass.

Thirdly, the use of conventional vasopressor agents as phenylephrine, norepinephrine, and vasopressin. Finally, the use of some off-label agents as vitamin C, hydroxocobalamin, angiotensin 2, methylene blue and prostaglandin inhibitors. (8)

1.4. Why this clinical trial?

The use of norepinephrine during CPB has its own potential benefits. It is not clear if the use of continuous norepinephrine infusion during CPB would be effective and safe in lessening the postoperative hyperlactatemia and development of vasoplegia after cardiac surgery.

The here proposed randomized controlled clinical trial will test the use of continuous norepinephrine infusion during CPB with respect to the efficacy and safety to reduce the postoperative rise in blood lactate level.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status between ІІІ and ІV
  • Scheduled for any type of elective cardiac surgery using CPB
  • General anesthesia provided in an endotracheally intubated patient.

Exclusion criteria

  • Decline consent to participate.
  • Emergency surgery.
  • Ejection fraction (EF%) less than 35%.
  • Scheduled for re-do surgery.
  • Scheduled for emergency surgery.
  • Preoperative ventilator or circulatory support.
  • Body mass index (BMI) greater than 40 Kg/m2.
  • History of alcohol abuse.
  • History of drug abuse.
  • Pregnancy.
  • Consent for another interventional study during anaesthesia
  • No written informed consent.

Treatment and study plan

Placebo

Drug

Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.

norepinephrine

Drug

Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.

Increase infusion rate

Other

Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments

Decrease infusion rate

Other

Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements

Primary outcomes

  1. Changes in lactic acid level

    Time frame: For 24 hours after surgery from the start of surgery

    perioperative changes in lactic acid level measured from arterial or venous blood

Secondary outcomes

  1. Mean Arterial Pressure (MAP)

    Time frame: For 24 hours after surgery from the start of surgery

    invasive arterial blood pressure measurement

  2. Cardiac Index (CI)

    Time frame: For 24 hours after surgery from the start of surgery

    measured as l/min/m2

  3. Systemic Vascular Resistance index (SVRI)

    Time frame: For 24 hours after surgery from the start of surgery

    measured as dynes.sec.m2/cm5

  4. Stroke volume variation (SVV)

    Time frame: For 24 hours after surgery from the start of surgery

    measured as ml/min/m2

  5. Need for rescue doses of phenylephrine

    Time frame: For the time of surgery

    Use of rescue doses of phenylephrine

  6. Need for rescue doses of norepinephrine

    Time frame: For the time of surgery

    Use of rescue doses of norepinephrine

  7. Need for rescue doses of ephedrine

    Time frame: For the time of surgery

    Use of rescue doses of ephedrine

  8. Need for rescue doses of nitroglycerine

    Time frame: For the time of surgery

    Use of rescue doses of nitroglycerine

  9. Need for rescue doses of labetalol

    Time frame: For the time of surgery

    Use of rescue doses of labetalol

  10. Need for rescue doses of esmolol

    Time frame: For the time of surgery

    Use of rescue doses of esmolol

  11. Need for rescue doses of atropine

    Time frame: For the time of surgery

    Use of rescue doses of atropine

  12. Need for rescue doses of glycopyrrolate.

    Time frame: For the time of surgery

    Use of rescue doses of glycopyrrolate

  13. Intraoperative hypoxemia

    Time frame: For the time of surgery

    Decrease of peripheral oxygen saturation less than 92%

  14. Intraoperative hypercapnia

    Time frame: For the time of surgery

    Increase in end tidal carbon dioxide more than 45 mm Hg

  15. Intraoperative hypotension

    Time frame: For the time of surgery

    Number of drops in systolic arterial pressure < 90 mmHg for 3 minutes or longer for any reasons

  16. Intraoperative bradycardia

    Time frame: For the time of surgery

    Number of drops in heart rate lower than 40 beats.min-1 or 10% of baseline value for more than three minutes for any reasons.

  17. Intraoperative myocardial ischemic episodes

    Time frame: For the time of surgery

    Remarkable ischemic changes included those patients with ≥ 1- mv ST-segment depression or ≥ 2-mv ST-segment elevation lasting more than 1 minute

  18. Number of patients who required pacemaker insertion

    Time frame: For the time of surgery

    Need for pacemaker insertion following termination of cardiopulmonary bypass.

  19. Number of patients who required direct current shocks

    Time frame: For the time of surgery

    Need for direct current shock following termination of cardiopulmonary bypass..

  20. Number of patients who need for epinephrine

    Time frame: For the time of surgery

    Need for epinephrine following termination of cardiopulmonary bypass.

  21. Number of patients who need for norepinephrine

    Time frame: For the time of surgery

    Need for norepinephrine following termination of cardiopulmonary bypass.

  22. Number of patients who need for dobutamine

    Time frame: For the time of surgery

    Need for dobutamine following termination of cardiopulmonary bypass.

  23. Number of patients who need for milrinone

    Time frame: For the time of surgery

    Need for milrinone following termination of cardiopulmonary bypass.

  24. Number of patients who need for for Intra-Aortic Balloon Pump

    Time frame: For the time of surgery

    Need for intra-aortic balloon counter pulsation pump following termination of cardiopulmonary bypass.

  25. Intraoperative need for blood transfusion

    Time frame: For the time of surgery

    The amount of transfused units of blood and blood products

  26. Intraoperative fluid intake

    Time frame: For the time of surgery

    The amount of infused crystalloids and colloids

  27. ICU Stay

    Time frame: For 30 days after surgery

    Length of ICU stay

  28. Hospital Stay

    Time frame: For 30 days after surgery

    Length of hospital stay

  29. Mortality at 30 days

    Time frame: For 30 days after surgery

    Alive or dead on postoperative day 30

  30. Mortality at 90 days

    Time frame: For 90 days after surgery

    Alive or dead on postoperative day 90

  31. Postoperative need for reintubation

    Time frame: For 30 days after surgery

    Postoperative need for reintubation during the first 30 days following surgery

  32. Postoperative bleeding

    Time frame: For 30 days after surgery

    Postoperative bleeding during the first 30 days following surgery

  33. Postoperative cardiogenic shock

    Time frame: For 30 days after surgery

    Postoperative cariogenic shock for the first 30 days following surgery

  34. Postoperative acute kidney injury

    Time frame: For 30 days after surgery

    Postoperative acute kidney injury for the first 30 days following surgery

  35. Postoperative splanchnic ischemia

    Time frame: For 30 days after surgery

    Postoperative mesenteric or splanchnic ischemia for the first 30 days following surgery

  36. Postoperative myocardial ischemia

    Time frame: For 30 days after surgery

    Postoperative acute coronary syndrome for the first 30 days following surgery

  37. Postoperative wound infection

    Time frame: For 30 days after surgery

    Postoperative wound infection for the first 30 days following surgery

  38. Postoperative pneumonia

    Time frame: For 30 days after surgery

    Postoperative pneumonia for the first 30 days following surgery

  39. Postoperative mediastinitis

    Time frame: For 30 days after surgery

    Postoperative mediastinitis for the first 30 days following surgery

  40. Postoperative hypoxemia

    Time frame: For 30 days after surgery

    Postoperative decrease in peripheral oxygen saturation less than 90 for the first 30 days following surgery

  41. Postoperative stroke

    Time frame: For 30 days after surgery

    Postoperative stroke for the first 30 days following surgery

  42. Postoperative sternotomy

    Time frame: For 30 days after surgery

    Postoperatively during hospital stay

  43. Postoperative sternal dehiscence

    Time frame: For 30 days after surgery

    Postoperatively during hospital stay

Sponsors and collaborators

Lead sponsor

Imam Abdulrahman Bin Faisal University

Other

Registry information

Official study title

Effects of Norepinephrine Infusion During Cardiopulmonary Bypass on Perioperative Changes in Lactic Acid Level: A Randomized Controlled Study

Acronym: Norcal

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 18, 2020
Registry last updated
Dec 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.